Increasing traffic and industrialization are two prominent factors responsible for environmental pollution. Pollutants released in the environment can cause harmful effects on human health and can lead to allergies and asthma. For instance, over 4.3 million deaths occur due to pollution every year, Our World in Data Organization. Moreover, the prevalence of children suffering from asthma is increasing at an alarming rate, for instance, over 8% of children in the U.S. were diagnosed with asthma in 2016, American Academy of Allergy, Asthma & Immunology. Montelukast has been used in monotherapy and combination therapy and has shown positive results. In the last few years, manufacturers have come up with different ways to tackle asthma problem; innovative product portfolio is one of them. Today, AstraZeneca produces over 80 top-selling asthma drugs in the market.
Global montelukast intermediate market is expected to reach USD 8,715.3 thousand by 2026, growing at a CAGR of 4.71% during the forecast period, 2019–2026.
Global montelukast intermediate market is segmented by application and end-user.
Based on application, the market is segmented into asthma, allergic rhinitis, bronchospasm, and urticaria. Asthma segment is leading the market following its increasing prevalence worldwide.
By end-user, the market is segmented into biotechnology & pharmaceutical companies, laboratories, and others.
Biotechnology & pharmaceutical companies are dominating the market. Currently, a huge population is suffering from Asthma as the demand for asthma medication. Moreover, montelukast intermediate is paving its way in the manufacturing view, which, in turn, is increasing the market opportunities. In addition, India and china are a leading API manufacturing hub in the Asia Pacific region. Some of the major end-users are Aurobindo Pharma, Merck, and Glenmark. Aurobindo Pharma and Glenmark offer FDA approved generic montelukast sodium tablets, which are considered an alternative to Merck & Co's Singulair tablets. In 2016, Morepen Laboratories received selling rights for its anti-asthmatic drug Montelukast in North American and European markets.
Geographically, the global montelukast intermediate market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA).
North America is leading the global montelukast intermediate market as a result of the major presence of manufacturers in the region. Lack of monitoring in asthma regime has been a major complication in the North American healthcare system. According to a Canadian study, patients with uncontrolled asthma can avoid USD 7,923 per year in Canada with optimally controlled asthma. Moreover, the cost reduction can be achieved by controlling asthma symptoms with the help of proper medication regimen. In Latin America, stress, violence, parasitic infections, and use of biomass fuels are some of the major factors responsible for asthma.
Europe is projected to continue being the second-largest regional market in the years as a result of the presence of internationally renowned academics alongside leading pharmaceutical companies such as GSK and AstraZeneca. Together with world-class research into digital technologies and bioinformatics, the region offers high potential for advanced therapies. Moreover, asthma costs over USD 19.07 billion, and productivity losses add up to USD 10.9 billion annually in the EU.
Some of the key players in the global montelukast intermediate market are ORTIN LABORATORIES LIMITED (India), MANUS AKTTEVA (India), P.G.Shah & Co. (India), VIVAN Life Sciences (India), Arch Pharmalabs (India), Admiron Life Sciences Pvt Ltd (India), Zhejiang Tianyu Pharmaceutical Co. Ltd (China), and Actis Generics Pvt Ltd. (India).
By End user
The Middle East & Africa